NCT00981058 2025-06-18
SQUIRE
Eli Lilly and Company
Phase 3 Completed
Clinical Trials
9 trialsNCT02789345 2024-02-05
A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer
Eli Lilly and Company
Phase 1 Completed
NCT00982111 2022-01-11
INSPIRE
Eli Lilly and Company
Phase 3 Completed
NCT02443337 2020-12-09
A Study of LY3023414 and Necitumumab in Squamous Lung Cancer
Eli Lilly and Company
Phase 2 Terminated
NCT02392507 2020-11-19
A Study of Nab-Paclitaxel and Carboplatin Plus Necitumumab (LY3012211) in Participants With Stage IV Squamous NSCLC
Eli Lilly and Company
Phase 2 Completed
NCT01763788 2019-10-25
A Study of Necitumumab in the First-Line Treatment of Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)
Eli Lilly and Company
Phase 1/2 Completed
NCT01606748 2019-09-30
A Drug-Interaction Study of Necitumumab (IMC-11F8) in Combination With Gemcitabine-Cisplatin
Eli Lilly and Company
Phase 2 Completed
NCT01769391 2019-09-20
A Study of Necitumumab and Chemotherapy in Participants With Stage IV Squamous Non-Small Cell Lung Cancer
Eli Lilly and Company
Phase 2 Completed
NCT01788566 2016-06-27
A Study of Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab in the First-Line Treatment of Participants With Squamous Lung Cancer
Eli Lilly and Company
Phase 2 Completed